Dual targeting of Notch and Wnt/β-catenin pathways: Potential approach in triple-negative breast cancer treatment
- 14 October 2020
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 394 (3) , 481-490
Abstract
Despite the continuously growing repertoire of new and improved anti-cancer therapies, triple-negative breast cancer (TNBC) remains a clinical challenge to treat. In this sense, targeting signaling pathways such as Notch and Wnt/β-catenin have attracted growing attention. This work aimed at investigating the possible antitumor effects of IMR-1 as a Notch inhibitor, PRI-724 as a Wnt/β-catenin inhibitor, as well as their combination and to explore the possible crosstalk between Notch and Wnt/β-catenin signaling pathways in MDA-MB-231 TNBC cell line. Microculture tetrazolium test (MTT) was used to determine the drug growth inhibition (GI50), and the results were analyzed using CompuSyn 3.0.1 software. MDA-MB-231 cells were divided into four treatment groups including positive control, IMR-1-treated, PRI-724-treated, and combination-treated groups. Sandwich enzyme-linked immunosorbent assay (ELISA) was used for the determination of the protein levels of hairy and enhancer of split-1 (HES-1), Notch-1, β-catenin, cyclin-D1, and vascular endothelial growth factor (VEGF1). HES-1 gene expression was assessed by quantitative real-time polymerase chain reaction. Statistical analyses were performed using GraphPad Prism Software. The GI50 for IMR-1 and PRI-724 were 15.3 μM and 0.69 μM, respectively. Upon treatment of MDA-MB-231 cells with these drugs, HES-1 gene expression was up-regulated due to single and combined treatments. Moreover, the protein levels of cyclin-D1, VEGF1, HES-1, and Notch-1 were reduced, while those of active β-catenin and active caspase-3 were elevated. IMR-1/PRI-724 combination augmented IMR-1- and PRI-724-mediated effects on MDA-MB-231 cells by initiating apoptotic cell death. Further in vitro and in vivo studies are warranted to support our findings.Keywords
This publication has 32 references indexed in Scilit:
- Notch activation inhibits AML growth and survival: a potential therapeutic approachJournal of Experimental Medicine, 2013
- The Functional Role of Notch Signaling in Triple-Negative Breast Cancer2013
- The wnt/β‐catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancerJournal of Cellular Biochemistry, 2011
- Notch post-translationally regulates β-catenin protein in stem and progenitor cellsNature Cell Biology, 2011
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay MethodCancer Research, 2010
- Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancerBreast Cancer Research and Treatment, 2009
- Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancerProceedings of the National Academy of Sciences, 2009
- Critical Role of Endothelial Notch1 Signaling in Postnatal AngiogenesisCirculation Research, 2007
- Role of beta-catenin in regulating vascular endothelial growth factor A (VEGF-A) expression in endometrial cancerJournal of the American College of Surgeons, 2006
- A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcriptionProceedings of the National Academy of Sciences, 2004